<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Foghorn Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc</link>
<description>Latest news and press releases for Foghorn Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/foghorn-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68356bef78dffbe2df0f2cc1.webp</url>
<title>Foghorn Therapeutics Inc</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc</link>
</image>
<item>
<title>Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer - Selective EP300 degrader outperforms clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy - Robust degradation a</description>
</item>
<item>
<title>Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-financial-update-for-2025-and-2026-strategic-outlook-9</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-financial-update-for-2025-and-2026-strategic-outlook-9</guid>
<pubDate>Wed, 11 Mar 2026 20:09:00 GMT</pubDate>
<description>FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026 Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL) Completed a $50 million registered direct financing in January 2026 Strong balanc</description>
</item>
<item>
<title>Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-strengthens-financial-leadership-with-appointment-of-ryan-maynard-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-strengthens-financial-leadership-with-appointment-of-ryan-maynard-as-chief-financial-officer</guid>
<pubDate>Mon, 23 Feb 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance</description>
</item>
<item>
<title>Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-guggenheim-emerging-120000494</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-guggenheim-emerging-120000494</guid>
<pubDate>Tue, 03 Feb 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have t</description>
</item>
<item>
<title>Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-closing-50-210500185</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-closing-50-210500185</guid>
<pubDate>Tue, 13 Jan 2026 21:05:00 GMT</pubDate>
<description>WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered direct financing at a 30% premium. The registered direct offering included the sale of 2,030,314 shares of common stock at $6.71 per share (issue price). Certain investors received pre-funded warrants to</description>
</item>
<item>
<title>Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-highlights-january-equity-032000511</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-highlights-january-equity-032000511</guid>
<pubDate>Sat, 10 Jan 2026 03:20:00 GMT</pubDate>
<description>Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer on track to be IND-ready in 2026 Selective EP300 degrader program shows pr</description>
</item>
<item>
<title>Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-8th-annual-120000737</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-8th-annual-120000737</guid>
<pubDate>Tue, 25 Nov 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have t</description>
</item>
<item>
<title>Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-third-quarter-120000156</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-third-quarter-120000156</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+ breast cancer; IND-ready in 2026 Robust preclinical anti-tumor activity and favorable tolerability across hematological malignancies differentiate novel, Selective EP300 degrader from dual CBP/EP300 appr</description>
</item>
<item>
<title>Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-three-upcoming-123000795</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-three-upcoming-123000795</guid>
<pubDate>Mon, 03 Nov 2025 12:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Contr</description>
</item>
<item>
<title>Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-updates-selective-113000198</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-updates-selective-113000198</guid>
<pubDate>Thu, 30 Oct 2025 11:30:00 GMT</pubDate>
<description>- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors - Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and in ER+ breast cancer; IND-ready in 2026 - Selective EP300 degrader demonstrates efficacy and favorable tolerability in preclinical models in hematological malignancies with signifi</description>
</item>
<item>
<title>Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-significant-progress-110000332</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-significant-progress-110000332</guid>
<pubDate>Thu, 16 Oct 2025 11:00:00 GMT</pubDate>
<description>Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDTCAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced key development updates for its Selective ARID1B degrader program which</description>
</item>
<item>
<title>Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-second-quarter-110000943</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-second-quarter-110000943</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS inhibitors reinforces significant potential in NSCLC Selective CBP degrader on track for IND-enabling studies, targeting an IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader, wi</description>
</item>
<item>
<title>Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-four-upcoming-110000942</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-four-upcoming-110000942</guid>
<pubDate>Thu, 22 May 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen’s 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025</description>
</item>
<item>
<title>Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-first-quarter-110000973</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-first-quarter-110000973</guid>
<pubDate>Wed, 14 May 2025 11:00:00 GMT</pubDate>
<description>FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates ex</description>
</item>
<item>
<title>Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-citizens-life-110000797</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-citizens-life-110000797</guid>
<pubDate>Mon, 05 May 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Citizens Life Sciences Conference, being held May 7-8, 2025, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to tr</description>
</item>
<item>
<title>Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-appoints-neil-gallagher-110000970</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-appoints-neil-gallagher-110000970</guid>
<pubDate>Thu, 01 May 2025 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. “Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry,” said Adrian Gottschalk, President</description>
</item>
<item>
<title>Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-presents-preclinical-data-200500287</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-presents-preclinical-data-200500287</guid>
<pubDate>Mon, 28 Apr 2025 20:05:00 GMT</pubDate>
<description>- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors supports clinical exploration - Selective CBP degrader combination approaches show promise in preclinical ER+ breast cancer models - Further preclinical characterization of the therapeutic potential of the Selective EP300 degrader p</description>
</item>
<item>
<title>Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-host-virtual-investor-110000161</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-host-virtual-investor-110000161</guid>
<pubDate>Tue, 15 Apr 2025 11:00:00 GMT</pubDate>
<description>Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional updates include new preclinical data for Selective CBP degrader program in combination with chemotherapy and targeted agents and for Selective EP300 degrader program in hematological malignancies Virtual investor event to be held on Tuesday April 29, 2025, at 8 a.m. ET CAMBRIDGE, Mass</description>
</item>
<item>
<title>Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-preclinical-data-203500734</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-announces-preclinical-data-203500734</guid>
<pubDate>Tue, 25 Mar 2025 20:35:00 GMT</pubDate>
<description>- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical data for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers - Poster presentations on preclinical data for Selective CBP degrader in combination with chemotherapy and targeted agents and for Selective EP300 degrader in hematological malignancies</description>
</item>
<item>
<title>Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook</title>
<link>https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-financial-2024-210500380</link>
<guid isPermaLink="true">https://6ix.com/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-provides-financial-2024-210500380</guid>
<pubDate>Thu, 06 Mar 2025 21:05:00 GMT</pubDate>
<description>First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population FHD-909 preclinical combination data with pembrolizumab and KRAS inhibitors to be presented at AACR 2025 Selective degradation of ARID1B achieved with program update expected in 2025; continued progress of Selective CBP degrader and Selective EP300 degrader towards IND Strong ba</description>
</item>
</channel>
</rss>